Grant of Options

Alliance Pharma PLC
27 July 2007


For Immediate Release                                               27 July 2007





                              ALLIANCE PHARMA PLC
                         ('Alliance' or 'the Company')

                                Grant of Options


Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces
the following award of options over the Company's ordinary shares.


  Name    Position   Number of options  Exercise    Time of    Percentage
                         awarded         price      vesting    of issued
                                          per                   ordinary
                                         share                   share
                                                                capital

Richard   Finance        500,000         8.25p   11 July 2010     0.31%
Wright    Director

Tony      Sales &        105,000         9.25p     2 May 2010     0.06%
Booley    Marketing
          Director

Mark      Medical        610,000         9.25p     2 May 2010     0.38%
Tomlinson Director


Tony Booley has a total of 594,250 share options and an interest in 6,710,723
Ordinary Shares of the Company.



For further information:

Alliance Pharma plc                                         + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk

Numis Securities                                           + 44 (0) 20 7260 1000
David Poutney
Michael Meade

Buchanan Communications                                    + 44 (0) 20 7466 5000
Mark Court/Rebecca Skye Dietrich




Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 34 branded pharmaceutical products.

Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to pharmaceutical wholesalers which
service both hospital and retail pharmacies with their prescription
requirements.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.




                      This information is provided by RNS
            The company news service from the London Stock Exchange